NASDAQ:TWST Twist Bioscience Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Twist Bioscience Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $64.71 -2.01 (-3.01 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$64.59Now: $64.71▼$70.9250-Day Range$55.60MA: $65.45▼$71.7252-Week Range$18.52Now: $64.71▼$71.99Volume664,235 shsAverage Volume564,733 shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/ABeta0.43 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingTwist Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.00, Twist Bioscience has a forecasted downside of 35.1% from its current price of $64.71.Amount of Analyst CoverageTwist Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesTwist Bioscience has received 65 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTwist Bioscience has received 66 “underperform” votes. (Add your “underperform” vote.)Community SentimentTwist Bioscience has received 50.38% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Twist Bioscience and other stocks. Vote “Outperform” if you believe TWST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TWST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTwist Bioscience does not currently pay a dividend.Dividend GrowthTwist Bioscience does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,341,333.00 in company stock.Percentage Held by InsidersOnly 25.10% of the stock of Twist Bioscience is held by insiders.Percentage Held by Institutions82.99% of the stock of Twist Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Twist Bioscience are expected to grow in the coming year, from ($3.03) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Twist Bioscience is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Twist Bioscience is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTwist Bioscience has a P/B Ratio of 13.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TWST Previous Symbol CUSIPN/A CIKN/A Webwww.twistbioscience.com Phone800-719-0671Debt Debt-to-Equity Ratio0.01 Current Ratio10.98 Quick Ratio10.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$54.38 million Price / Sales53.15 Cash FlowN/A Price / Cash FlowN/A Book Value$4.63 per share Price / Book13.98Profitability EPS (Most Recent Fiscal Year)($3.92) Net Income$-107,670,000.00 Net Margins-199.98% Return on Equity-57.24% Return on Assets-44.72%Miscellaneous Employees289 Outstanding Shares44,663,000Market Cap$2.89 billion Next Earnings Date12/9/2020 (Estimated) OptionableNot Optionable $64.71 -2.01 (-3.01 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TWST News and Ratings via Email Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter. Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions How has Twist Bioscience's stock been impacted by COVID-19 (Coronavirus)? Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TWST shares have increased by 129.5% and is now trading at $64.71. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Twist Bioscience? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Twist Bioscience. When is Twist Bioscience's next earnings date? Twist Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, December 9th 2020. View our earnings forecast for Twist Bioscience. How were Twist Bioscience's earnings last quarter? Twist Bioscience Corp (NASDAQ:TWST) announced its earnings results on Thursday, August, 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The business had revenue of $21.20 million for the quarter, compared to analysts' expectations of $13.67 million. Twist Bioscience had a negative return on equity of 57.24% and a negative net margin of 199.98%. The firm's quarterly revenue was up 55.9% on a year-over-year basis. View Twist Bioscience's earnings history. What price target have analysts set for TWST? 2 brokers have issued 1-year target prices for Twist Bioscience's shares. Their forecasts range from $42.00 to $42.00. On average, they expect Twist Bioscience's stock price to reach $42.00 in the next year. This suggests that the stock has a possible downside of 35.1%. View analysts' price targets for Twist Bioscience. Are investors shorting Twist Bioscience? Twist Bioscience saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 4,200,000 shares, a drop of 12.5% from the August 15th total of 4,800,000 shares. Based on an average daily volume of 521,200 shares, the days-to-cover ratio is currently 8.1 days. Currently, 13.1% of the company's shares are sold short. View Twist Bioscience's Short Interest. Who are some of Twist Bioscience's key competitors? Some companies that are related to Twist Bioscience include argenx (ARGX), Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), Repligen (RGEN), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Spark Therapeutics (ONCE) and Ablynx (ABLYF). View all competitors. What other stocks do shareholders of Twist Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Pfizer (PFE), Crowdstrike (CRWD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Docusign (DOCU), Gilead Sciences (GILD), JD.Com (JD), Square (SQ), Intel (INTC) and Peloton (PTON). Who are Twist Bioscience's key executives? Twist Bioscience's management team includes the following people: Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)Mr. James M. Thorburn, Chief Financial Officer (Age 64)Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)Mr. William Charles Banyai, COO & Director (Age 64)Mr. Bill Peck, Chief Technology Officer (Age 59) When did Twist Bioscience IPO? (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers. What is Twist Bioscience's stock symbol? Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST." Who are Twist Bioscience's major shareholders? Twist Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.05%), FMR LLC (3.59%), Bank of New York Mellon Corp (2.39%), Sumitomo Mitsui Trust Holdings Inc. (2.38%), Alyeska Investment Group L.P. (1.79%) and Victory Capital Management Inc. (1.46%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green and William Banyai. View institutional ownership trends for Twist Bioscience. Which institutional investors are selling Twist Bioscience stock? TWST stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Cormorant Asset Management LP, William Blair Investment Management LLC, Asymmetry Capital Management L.P., Nicholas Investment Partners LP, Perceptive Advisors LLC, and Bank of America Corp DE. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, Emily M Leproust, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, Paula Green, and William Banyai. View insider buying and selling activity for Twist Bioscience. Which institutional investors are buying Twist Bioscience stock? TWST stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Goldman Sachs Group Inc., Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., Wasatch Advisors Inc., Alyeska Investment Group L.P., Essex Investment Management Co. LLC, and Driehaus Capital Management LLC. View insider buying and selling activity for Twist Bioscience. How do I buy shares of Twist Bioscience? Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Twist Bioscience's stock price today? One share of TWST stock can currently be purchased for approximately $64.71. How big of a company is Twist Bioscience? Twist Bioscience has a market capitalization of $2.89 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe. What is Twist Bioscience's official website? The official website for Twist Bioscience is www.twistbioscience.com. How can I contact Twist Bioscience? Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
